Founded by Bill Rader and Spencer Rosero, Efferent Labs was created from a clinical observation. Today, the company is preparing to commercialize a revolutionary platform that will change the way preclinical research is done for the better. More data, faster decisions, less cost.
Efferent Labs® offers a live, cellular data acquisition platform that will radically alter the landscape of pre-clinical research in animals.
Sign up for email alerts of Press Releases and Efferent Labs’ breaking news
Mr. Rader is a serial entrepreneur who sold his first company at age 18. To date he has launched five ventures and orchestrated multiple M&A’s. Mr. Rader founded Efferent Labs, Inc. in 2011 with a passion derived from his personal experience. He created Efferent Labs on the shoulders of a company he founded in 1998 and successfully exited in 2015, Raland Technologies (now Raland Compliance Partners). Mr. Rader grew Raland from a one-man startup to an Inc. 500|5000 company with a global footprint and four divisions. While leading Raland, he established strategic office locations and provided services to clients including Fortune 500 pharmaceutical, biotech and medical device companies throughout the United States, Europe and Asia. His efforts enabled Raland to become one of the most highly respected and sought after providers within the Life Science industry.
Mr. Rader started his career in the engineering sector of the U.S. Navy as a Nuclear Engineering Reactor Controls member of the Submarine Fleet. He holds a Bachelor of Science in Electrical Engineering, is a member of Harvard Business School, Business Innovations in Global Healthcare class of 2015, and a graduate of the University at Buffalo, School of Management. Mr. Rader is a NYBio Fellow, and a member of many industry organizations including ISPE, PDA, IEEE, MedTech, Tech Council/MDBio, and ISA.
Mr. Dillion acts as the companies Chief Accounting Officer, Vice President of Finance and Comptroller. He has years of experience in the role of finance officer from Controller and Senior Account to Chief Financial Officer, having served companies from Alltech and Trumpf Medical to Evening Post Publishing. Mr. Dillion is a CPA, and holds a BA in Accounting from Asbury College.
Dr. Rosero serves as the Chief Medical Officer of Efferent Labs, Inc. working with the Scientific Advisors and directing discovery activity.
Dr. Rosero is Professor of Medicine at the University of Rochester School of Medicine and Dentistry. He currently serves as Director of the Clinical Research Center -the Clinical and Translational Sciences Institute (CTSI) and as Clinical Director of the Center for Medical Technology and Innovation at the University of Rochester. He is a practicing cardiologist who developed the CytoComm™ and PlexiSense technology through years of work with patients. As a specialist in heart rhythm disorders, Dr. Rosero treats patients using a wide range of therapeutic options including radiofrequency ablation of abnormal rhythms, implantation of electronic medical devices such as pacemakers, defibrilllators (ICD’s), and cardiac resynchronization therapy devices.
Dr. Rosero is an experienced clinical investigator and has actively participated in several, large multicenter trials studying the role of medical devices in treating patients with heart failure and life threatening arrhythmias. As the site principal investigator for the early evaluation of a novel implantable left atrial pressure monitoring system at the University of Rochester, Dr. Rosero’s team was the first in the nation to implant the St. Jude Heart Pod device. His research interests include living cell embedded biosensors, hereditary arrhythmias and futuristic medical device technologies that support personalization of medical care.
Kathryn McIlroy is a 25-year veteran of the life sciences industry. With experience across a broad range of fundamental and preclinical research platforms Kathryn runs all day-to-day activities of the lab. She also liaisons with our partner companies in her role as Lab Manager.
During her career she has setup and managed a variety of wet lab space with responsibility for equipment, training, and budgets. The companies she has been part of have taken compounds from the bench through GLP evaluation and analysis.
Additionally, she has managed collaborative efforts across multiple disciplines, contract research organizations and vendors to deliver on time and within budget.
A key skillset that she brings to the team at Efferent is project management across the early phase testing and development of programs. Her years of experience within the biology and engineering worlds enable her to seamlessly traverse the different teams to create a cohesive vision and tactical program.
Ms. McIlroy holds a MSc in physiology and pharmacology from McMaster University (Hamilton Canada) and a BSc in Biology from the University of Waterloo (Waterloo, Canada).
Mr. Colpoys is an experienced executive in the biopharma/medtech industry. Since leaving Genentech in 1995, he has been involved in the startup and structuring of more than a dozen companies as either an active member of senior management or in his role as a consultant via his activities as President of Galileo Consulting, Inc. His 30 years of experience across a broad range of operational activities makes him a valued associate at Efferent Labs. Mr. Colpoys assist’s in the formulation of strategy and communication with potential collaborators and licensees.
Dr. McIlroy began his career at the National Medical Laser Center in London England that is part of the University of London. While there he was responsible for all the laser treatments and maintenance of the clinical and non-clinical laser systems. While working at NMLC he also carried out a PhD in the specialized area of Photodynamic Therapy Dosimetry (PDT. Dr,. McIlroy then moved on to work with the research group in the area of PDT at the Ontario Caner Institute in Toronto. He was then recruited to North Carolina in 2000 as Director of Science, to set up the PDT program at the Leo Jenkins Cancer Center in Greenville North Carolina. While there he was responsible for setting up the infrastructure, the clinical program as well as a scientific program within the department of Physics.
Dr. McIlroy moved to GE Global Research in Albany NY as the head of a new program in Bioinstumentation. Over the course of his tenure at GE Research he held many roles finishing as a global technical leader responsible for all advanced technology across 4 GE Healthcare business units, with 75+ people and a budget responsibility of $40M.
He was then promoted into what became GE Ventures as the Healthcare leader responsible for monetizing the technology and knowhow across GE Healthcare. Later he was promoted to Managing Director for Alliance management for North and South America with the entire GE portfolio of 95,000 articles of IP from all business units.
Overall Dr. McIlroy has over 20 years experience in all aspects of medical device development together with management of clinical trials ranging from preclinical through phase III FDA controlled global trials.
Mr. Greco, an entrepreneur and venture advisor and founder of Cupule Ventures, provides venture development and support to early stage Biotech, Life Science, Material Science and Technology companies, concentrated across Upstate New York. Taking a hands-on role, Greco manages executive, financial and operational functions, as his efforts have centered in formation, management, fundraising and growing commercial operations. Instrumental in the launching and growth of 20+ start-ups, primarily of higher technology or advance manufacturing pedigrees, Greco managed the investment efforts of 10+ successful private placements and managed several acquisitions, domestic and international.
Previous to founding Cupule, Greco was a Venture Associate on two funds with Trillium Group, LLC, in Rochester, NY, eclipsing $135M in investments and has deep entrepreneurial roots of his own, starting his first company in 2003. He has an M.B.A. from the Simon School of Business Administration and a B.A. in Economics from the University of Rochester.
